Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 136 Published: November 30, 2021 Report Code: GMDGDHC13164IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    Text to Speech

The progressive supranuclear palsy market research report provides comprehensive information on the therapeutics under development for progressive supranuclear palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for progressive supranuclear palsy and features dormant and discontinued projects.

What are the key targets in the progressive supranuclear palsy pipeline market?

The key targets in the progressive supranuclear palsy pipeline market are Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, Mercury, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD, Protein Phosphatase 2A, and Reverse Transcriptase. Microtubule Associated Protein Tau has the highest number of pipeline products in the progressive supranuclear palsy market.

Progressive supranuclear palsy pipeline market, by targets

Progressive supranuclear palsy pipeline market, by targets

For more target insights, download a free sample

What are the key MoA in the progressive supranuclear palsy pipeline market?

The key MoA in the progressive supranuclear palsy pipeline market are Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, Major Prion Protein Inhibitor, Mercury Chelator, and Protein Phosphatase 2A Activator. Microtubule Associated Protein Tau Inhibitor has the highest number of pipeline products in the progressive supranuclear palsy pipeline market.

Progressive supranuclear palsy pipeline market, by MoA

Progressive supranuclear palsy pipeline market, by MoA

For more MoA insights, download a free sample

What are the key RoA in the progressive supranuclear palsy pipeline market?

The key RoA in the progressive supranuclear palsy pipeline market are Oral, Intravenous, Subcutaneous, Intrathecal, and Parenteral. Oral has the highest number of pipeline products in the progressive supranuclear palsy pipeline market.

Progressive supranuclear palsy pipeline market, by RoA

Progressive supranuclear palsy pipeline market, by RoA

For more RoA insights, download a free sample

What are the key molecule types in the progressive supranuclear palsy pipeline market?

The key molecule types in the progressive supranuclear palsy pipeline market are Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine. Small Molecule has the highest number of pipeline products in the progressive supranuclear palsy pipeline market.

Progressive supranuclear palsy pipeline market, by molecule type

Progressive supranuclear palsy pipeline market, by molecule type

For more molecule type insights, download a free sample

What are the key companies in the progressive supranuclear palsy pipeline market?

The key companies in the progressive supranuclear palsy pipeline market are AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, AbbVie Inc, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Aprinoia Therapeutics Inc, Arvinas Inc, Asahi Kasei Pharma Corp, and Asceneuron SA.

Progressive supranuclear palsy pipeline market, by companies

Progressive supranuclear palsy pipeline market, by companies

To know more about key companies, download a free sample

Market report overview

Key targets Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, Mercury, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD, Protein Phosphatase 2A, and Reverse Transcriptase
Key MoA Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, Major Prion Protein Inhibitor, Mercury Chelator, and Protein Phosphatase 2A Activator
Key RoA Oral, Intravenous, Subcutaneous, Intrathecal, and Parenteral
Key molecule type Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine
Key companies AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, AbbVie Inc, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Aprinoia Therapeutics Inc, Arvinas Inc, Asahi Kasei Pharma Corp, and Asceneuron SA

Scope

  • The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy
  • The report reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects.
  • The report assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

AbbVie Inc

Allyx Therapeutics Inc

Alterity Therapeutics Ltd

AlzProtect SAS

Anhorn Medicines Co Ltd

Aprinoia Therapeutics Inc

Arvinas Inc

Asahi Kasei Pharma Corp

Asceneuron SA

AZTherapies Inc

Cortice Biosciences Inc

EmeraMed Ltd

Merck & Co Inc

NeuroTau Inc

New Amsterdam Sciences Inc

Novartis AG

Pinteon Therapeutics Inc

Prothena Corp Plc

Retrotope Inc

TauC3 Biologics Ltd

TauRx Therapeutics Ltd

Transposon Therapeutics Inc

UCB SA

Unity Biotechnology Inc

Vaxxinity Inc

Velacor Therapeutics Pty Ltd

Verge Genomics Inc

Voyager Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Global Markets Direct Report Coverage

Progressive Supranuclear Palsy – Overview

Progressive Supranuclear Palsy – Therapeutics Development

Progressive Supranuclear Palsy – Therapeutics Assessment

Progressive Supranuclear Palsy – Companies Involved in Therapeutics Development

Progressive Supranuclear Palsy – Drug Profiles

Progressive Supranuclear Palsy – Dormant Projects

Progressive Supranuclear Palsy – Discontinued Products

Progressive Supranuclear Palsy – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Progressive Supranuclear Palsy – Pipeline by AbbVie Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Allyx Therapeutics Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Alterity Therapeutics Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by AlzProtect SAS, 2021

Progressive Supranuclear Palsy – Pipeline by Anhorn Medicines Co Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by Aprinoia Therapeutics Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Arvinas Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Asahi Kasei Pharma Corp, 2021

Progressive Supranuclear Palsy – Pipeline by Asceneuron SA, 2021

Progressive Supranuclear Palsy – Pipeline by AZTherapies Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Cortice Biosciences Inc, 2021

Progressive Supranuclear Palsy – Pipeline by EmeraMed Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by Merck & Co Inc, 2021

Progressive Supranuclear Palsy – Pipeline by NeuroTau Inc, 2021

Progressive Supranuclear Palsy – Pipeline by New Amsterdam Sciences Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Novartis AG, 2021

Progressive Supranuclear Palsy – Pipeline by Pinteon Therapeutics Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Prothena Corp Plc, 2021

Progressive Supranuclear Palsy – Pipeline by Retrotope Inc, 2021

Progressive Supranuclear Palsy – Pipeline by TauC3 Biologics Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by TauRx Therapeutics Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by Transposon Therapeutics Inc, 2021

Progressive Supranuclear Palsy – Pipeline by UCB SA, 2021

Progressive Supranuclear Palsy – Pipeline by Unity Biotechnology Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Vaxxinity Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Velacor Therapeutics Pty Ltd, 2021

Progressive Supranuclear Palsy – Pipeline by Verge Genomics Inc, 2021

Progressive Supranuclear Palsy – Pipeline by Voyager Therapeutics Inc, 2021

Progressive Supranuclear Palsy – Dormant Projects, 2021

Progressive Supranuclear Palsy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

The key targets in the progressive supranuclear palsy pipeline market are Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, Mercury, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD, Protein Phosphatase 2A, and Reverse Transcriptase. Microtubule Associated Protein Tau has the highest number of pipeline products in the progressive supranuclear palsy market.

The key MoA in the progressive supranuclear palsy pipeline market are Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, Major Prion Protein Inhibitor, Mercury Chelator, and Protein Phosphatase 2A Activator. Microtubule Associated Protein Tau Inhibitor has the highest number of pipeline products in the progressive supranuclear palsy pipeline market.

The key RoA in the progressive supranuclear palsy pipeline market are Oral, Intravenous, Subcutaneous, Intrathecal, and Parenteral. Oral has the highest number of pipeline products in the the progressive supranuclear palsy pipeline market.

The key molecule types in the progressive supranuclear palsy pipeline market are Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine. Small Molecule has the highest number of pipeline products in the progressive supranuclear palsy pipeline market.

The key companies in the progressive supranuclear palsy pipeline market are AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, AbbVie Inc, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Aprinoia Therapeutics Inc, Arvinas Inc, Asahi Kasei Pharma Corp, and Asceneuron SA.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.